New research on hematopoietic stem cell transplantation (HCT) survivors reveals that while growth hormone therapy can help children who received transplants for life-threatening cancers and disorders grow taller, individual responses to treatment vary significantly.
New research on hematopoietic stem cell transplantation (HCT) survivors reveals that while growth hormone therapy can help children who received transplants for life-threatening cancers and disorders grow taller, individual responses to treatment vary significantly.
Research from Karolinska Institutet published in BMC Medicine reveals that the types of cells surrounding a breast tumor may influence the long-term effectiveness of tamoxifen hormone therapy, potentially helping identify which patients benefit most from the treatment.
Two patients with SCN2A-related developmental epileptic encephalopathy experienced reductions in seizure frequency after receiving individualized allele-selective antisense oligonucleotides. The treatments were well tolerated, with no ASO-related serious adverse events reported in two parallel single-patient studies published in Nature Medicine.
Researchers report safety and preliminary efficacy results from a phase Ib clinical trial testing personalized neoantigen-pulsed autologous dendritic cell vaccination in patients with newly diagnosed glioblastoma, a deadly brain cancer with limited treatment options.
New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.
British researchers have created a new diagnostic tool designed to identify individuals most at risk of developing obesity-related diseases, which could help target weight-loss medications to those who would benefit most from treatment.
International research led by RIKEN Center for Integrative Medical Sciences discovered new associations between pathogenic BRCA1 and BRCA2 gene variants and four additional cancer types beyond the previously known breast and ovarian cancers.
